Document:

<PAGE>
                                                                   Exhibit 10.16

[LIPID SCIENCES LOGO]

                              EMPLOYMENT AGREEMENT

      THIS EMPLOYMENT AGREEMENT (the "Agreement"), which is effective as of July
18, 2001, is between Lipid Sciences, Inc., a Delaware corporation (the
"Company"), and Jan Johansson ("Executive"), who agree as follows. The Company
and Executive are hereinafter collectively referred to as the "Parties," and may
individually be referred to as a "Party."

                                    RECITALS

      A.    The Company desires assurance of the association and services of
Executive in order to retain Executive's experience, skills, abilities,
background and knowledge, and is willing to engage Executive's services on the
terms and conditions set forth in this Agreement; and

      B.    Executive desires to be in the employ of the Company and is willing
to accept this employment on the terms and conditions set forth in this
Agreement.

                                    AGREEMENT

      1.    EMPLOYMENT.

            1.1   The Company will employ Executive, and Executive hereby
accepts employment by the Company, upon the terms and conditions set forth in
this Agreement, effective as of first Date of Hire (to be negotiated upon mutual
consent subsequent to an initial visit to Australia, fully paid by the Company,
and final approval by the President/CEO) for the term of one year from the Date
of Hire. This agreement will automatically be renewed for the term of one year
unless either party gives notice to the other at least 60 days prior to the
expiration of the then current term of employment of such party's intention not
to renew.

            1.2   Executive will be the Vice President of Research. Executive
will report to the President/CEO.

            1.3   Executive will do and perform all services, acts or things
necessary or advisable to manage and conduct the Research of the Company,
provided, however, that at all times during his employment Executive will be
subject to the direction of the President/CEO. Executive's duties will include,
but not be limited to, participation in the creation and management of the
overall strategy of the Company's research plan, it's clinical application
platforms, the external research process with outside vendors, the Company's
training programs as well as the preparation of the annual budget for his
department, and assist in the Company areas of new business development and
regulatory affairs. The Company acknowledges the non-competition agreement
Executive entered into with Esperion. During the first year of this Agreement,
Executive shall not provide any services nor act with respect to
biopharmaceuticals,

                                  Page 1 of 5
<PAGE>
plasma-derived apolipoprotein A-1 or any recombinant variant(s) thereof, or
synthetic HDL (parental therapies). Executive shall not disclose any information
that is confidential to Esperion.

            1.4   Unless the Parties otherwise agree in writing, prior to
Executive's termination in accordance with this Agreement, Executive will
perform the services he is required to perform in accordance with the terms of
this Agreement, reporting to the Company's offices and the President/CEO.

      2.    LOYAL AND CONSCIENTIOUS PERFORMANCE; NONCOMPETITION.

            2.1   During his employment by the Company, Executive will devote
his full business employment, interest, abilities and productive time to the
proper and efficient performance of his duties under this Agreement. Executive
may not be employed by another company or receive compensation for employment
from any other sources.

            2.2   During his employment by the Company, Executive may not engage
in competition with the Company, either directly or indirectly, in any manner or
capacity, as adviser, principal, agent, partner, officer, director, employee,
member of any association or otherwise, in any phase of the business of
developing, manufacturing and marketing of products that are in the same field
of use or which otherwise directly compete with the products or proposed
products of the Company.

            3.    COMPENSATION OF EXECUTIVE.

            3.1   The Company will pay Executive a salary of two hundred
thousand dollars ($200,000.00) per year ("Base Salary"), payable in regular
periodic payments in accordance with Company policy. Such salary will be
prorated for any partial year of employment on the basis of a 365-day fiscal
year.

            3.2   Executive's compensation may be changed from time to time by
mutual agreement of Executive the CEO and Board of Directors.

            3.3   All of Executive's compensation is subject to customary
withholding taxes and any other employment taxes as are commonly required to be
collected or withheld by the Company.

            3.4   Executive will, in the discretion of the Board and in
accordance with Company policy, be entitled to participate in benefits under any
employee benefit plan or arrangement made available by the Company now or in the
future to its executives and key management employees.

            3.5   Executive's performance will be reviewed by the CEO on a
periodic basis (not less than once each fiscal year). The CEO with approval of
the Board may, in their sole discretion, award bonuses to Executive as will be
appropriate or desirable based on Executive's performance. Executive will be
reviewed within twelve months of commencing employment hereunder.

                                  Page 2 of 5
<PAGE>
            3.6   Executive will be granted options to purchase the Company's
common stock. The Company will grant Executive an option to purchase up to one
hundred thousand (100,000) shares of the Company's common stock. The exercise
price per share of these options (the "Options") will be equal to $7.15 per
share. Options will vest as to twelve thousand five hundred (12,500) shares
following the first six (6) continuous months of service with the Company and
the remainder over three and one half years at the rate of 1/42nd per month of
the total 100,000 shares.

            3.7   Executive is entitled to receive prompt reimbursement of all
reasonable expenses incurred by Executive in performing Company services,
including expenses related to travel, entertainment, parking, and business
meetings. These expenses will be accounted for in accordance with the policies
and procedures established by the Company.

      4.    TERMINATION: Either party may terminate this Agreement and
Executive's employment without cause, upon thirty (30) days written notice. Upon
termination, the Company will be released from any and all obligations under
this Agreement, except in the event the Executive's employment is involuntarily
terminated by the Company for other than "good cause," then Executive will
resign from all positions with the Company, and enter into a consulting
arrangement for four (4) months commencing immediately after the termination
date. In consideration for such consulting arrangement, Executive will continue
to be paid salary and benefits for four (4) months. However, if Executive
obtains new full time employment during such four (4) month period, any salary
paid pursuant to such arrangement will be offset from amounts due under this
Letter Agreement. Executive's obligations under Paragraph 5 of this Agreement
will continue beyond his termination of employment.

      5.    CONFIDENTIAL INFORMATION; NONSOLICITATION.

            5.1   Executive recognizes that his employment with the Company will
involve contact with information of substantial value to the Company, which is
not old and generally known in the trade, and which gives the Company an
advantage over its competitors who do not know or use it, including but not
limited to, techniques, designs, drawings, processes, inventions, developments,
equipment, prototypes, sales and customer information, and business and
financial information relating to the business, products, practices and
techniques of the Company (hereinafter referred to as "Confidential
Information"). Executive will at all times regard and preserve as confidential
such Confidential Information obtained by Executive from whatever source and
will not, either during his employment with the Company or thereafter, publish
or disclose any part of such Confidential Information in any manner at any time,
or use the same except on behalf of the Company, without the prior written
consent of the Company; provided, however, that Executive may disclose
Confidential Information in the best interest of the Company with properly
executed Company confidentiality or secrecy agreements with the third party. As
a condition of this Agreement, the Executive will sign and return a copy of the
Company's Proprietary Information and Inventions Agreement, attached as EXHIBIT
A.

            5.2   While employed by the Company and for one (1) year thereafter,
in order to protect the Company's confidential and proprietary information from
unauthorized use, Executive may not, either directly or through others, (i)
solicit or attempt to solicit any employee, consultant or independent contractor
of the Company to terminate his or her relationship with the

                                  Page 3 of 5
<PAGE>
Company in order to become an employee, consultant or independent contractor to
or for any other person or business entity; or (ii) solicit or attempt to
solicit the business of any customer, vendor or distributor of the Company
which, at the time of termination or one (1) year immediately prior thereto, was
listed on the Company's customer, vendor or distributor list.

      6.    SUCCESSORS. The Company will require any successor (whether direct
or indirect, by purchase, merger, or consolidation) to all or substantially all
of the business and/or assets of the Company, by agreement in form and substance
reasonably satisfactory to the Executive, to expressly assume and agree to
perform this Agreement in the same manner and to the same extent that the
Company would be required to perform it if no such succession had taken place.

      7.    ASSIGNMENT AND BINDING EFFECT. This Agreement is binding on and
inures to the benefit of Executive and Executive's heirs, executors, personal
representatives, assigns, administrators and legal representatives. Because of
the unique and personal nature of Executive's duties under this Agreement,
neither this Agreement nor any rights or obligations under this Agreement are
assignable by Executive. This Agreement is binding on and inures to the benefit
of the Company and its successors, assigns and legal representatives.

      8.    NOTICES. All notices or demands of any kind required or permitted to
be given by the Company or Executive under this Agreement will be given in
writing and will be personally delivered (and receipted for) or mailed by
certified mail, return receipt requested, postage prepaid.

      9.    CHOICE OF LAW. This Agreement will be construed and interpreted in
accordance with the laws of the State of California, without regard to the
conflict of laws provision thereof.

      10.   INTEGRATION. This Agreement contains the complete, final and
exclusive agreement of the Parties relating to the subject matter of this
Agreement, and supersedes all prior oral and written employment agreements or
arrangements between the Parties.

      11.   AMENDMENT. This Agreement may not be amended or modified except by a
written agreement signed by Executive and the Company.

      12.   WAIVER. No term, covenant or condition of this Agreement or any
breach thereof will be deemed waived, except with the written consent of the
Party against whom the wavier in claimed, and any waiver or any such term,
covenant, condition or breach will not be deemed to be a waiver of any preceding
or succeeding breach of the same or any other term, covenant, condition or
breach.

      13.   SEVERABILITY. The finding by a court of competent jurisdiction of
the unenforceability, invalidity or illegality of any provision of this
Agreement will not render any other provision of this Agreement unenforceable,
invalid or illegal. Such court will have the authority to modify or replace the
invalid or unenforceable term or provision with a valid and enforceable term or
provision which most accurately represents the parties' intention with respect
to the invalid or unenforceable term or provision.

                                  Page 4 of 5
<PAGE>
      14.   INTERPRETATION; CONSTRUCTION. The headings set forth in this
Agreement are for convenience of reference only and will not be used in
interpreting this Agreement. Executive has been encouraged, and has consulted
with, his own independent counsel and tax advisors with respect to the terms of
this Agreement. The Parties acknowledge that each Party and its counsel has
reviewed and revised, or had an opportunity to review and revise, this
Agreement, and the normal rule of construction to the effect that any
ambiguities are to be resolved against the drafting party will not be employed
in the interpretation of this Agreement.

      15.   REPRESENTATIONS AND WARRANTIES. Executive represents and warrants
that, to the best of Executive's knowledge, he is not restricted or prohibited,
contractually or otherwise, from entering into and performing each of the terms
and covenants contained in this Agreement, and that his execution and
performance of this Agreement will not violate or breach any other agreements
between Executive and any other person or entity.

      16.   COUNTERPARTS. This Agreement may be executed in two counterparts,
each of which will be deemed an original, all of which together will contribute
one and the same instrument.

      17.   ARBITRATION. If any dispute arises regarding the application,
interpretation, or enforcement of this Agreement, including fraud in the
inducement, the dispute will be resolved by final and binding arbitration before
one arbitrator at the Judicial Arbitration and Mediation Service in Pleasanton,
California. The decision of the arbitrator will be final and may not be appealed
by either of the Parties.

      18.   ATTORNEYS' FEES AND COSTS. The prevailing party in any dispute
arising out of this Agreement, will be entitled to reimbursement by the losing
party of all of its or his attorneys' fees and costs including, but not limited
to, arbitrator's fees and expert's fees.

      IN WITNESS WHEREOF, the Parties have executed this Agreement as of the
date first above written.

THE COMPANY:                        LIPID SCIENCES, INC.

                                    By:   /s/ Phil Radlick
                                       _________________________________
                                          Phil Radlick
                                          President/CEO

EXECUTIVE:                                /s/ Jan Johansson
                                       ____________________________________
                                          Jan Johansson

                                  Page 5 of 5<PAGE>
                                                                   Exhibit 10.19

                              LIPID SCIENCES, INC.

                        INCENTIVE STOCK OPTION AGREEMENT

         THIS AGREEMENT is between Lipid Sciences, Inc., a Delaware corporation
(the "Company"), and _________________ whose signature is set forth on the
signature page hereof ("Participant").

                                    RECITALS

         WHEREAS, the Company has adopted the Lipid Sciences, Inc. 2000 Stock
Option Plan, (the "Plan"), which provides for the grant of incentive stock
options to Employees and other eligible individuals;

         WHEREAS, Participant is an Employee and is in a position to contribute
materially to the continued growth and development and the future financial
success of the Company;

         WHEREAS, the Company wishes to grant to Participant an incentive stock
option to purchase common stock of the Company (the "Common Stock") on the terms
and conditions specified herein to provide a means for the Participant to
participate in the future growth of the Company and to increase the
Participant's incentive and personal interest in the continued success and
growth of the Company; and

         NOW, THEREFORE, the parties agree as follows (any capitalized terms
used herein but not defined herein will have the respective meanings given in
the Plan):

1.       Option.

         (a) Grant. Subject to the terms and conditions of this Agreement and
the Plan, the Company hereby grants to Participant an Incentive Stock Option to
purchase all or any part of the shares set forth on the signature page hereof,
at the exercise price set forth on the signature page hereof. The Option is
intended to be an "incentive stock option" as defined in Section 422 of the
Code.

         (b) Term. The term of the Option will expire at 11:59 p.m. on the date
which is 10 years following the date of grant of the Option.

         (c) Vesting. Options will vest as to __________ shares following the
first ___ continuous months of service with the Company and the remainder over
___ years at the rate ___ per month of the total ________ shares.

      2.    Exercise. The Option may not be exercised prior to the date it is
vested or after the expiration date. Participant may, subject to the limitations
of this Agreement and the Plan, exercise all or any portion of the Option that
has vested pursuant to

<PAGE>
Section 1 hereof by providing written notice of exercise to the Company
specifying the number of shares with respect to which the Option is being
exercised and accompanied by payment of the exercise price for such shares. The
exercise price will be paid in cash, by certified check or cashier's check
payable to the Company, or by the surrender of a whole number of previously
owned shares (free of all adverse claims and duly endorsed in blank by
Participant or accompanied by stock powers duly endorsed in blank) having a Fair
Market Value on the date of exercise equal to the exercise price. Upon full
payment of the exercise price, the Company will promptly deliver to the
Participant a certificate or certificates for the number of Shares in respect of
which the Option has been exercised, legended as described herein and as
required by applicable law. No portion of the Option may be exercised after it
has expired pursuant to Section 1 hereof.

      3.  Termination of Employment.

         (a) If the employment of Participant terminates by reason of
disability, Participant (or his or her legal representative) may exercise any
portion of the Option which has vested pursuant to Section 1 hereof as of the
date of such termination of employment for a period of one year after the date
of such termination of employment and not thereafter; provided, however, that no
Option or portion thereof will be exercisable after it has expired pursuant to
Section 1 hereof. For purposes of this Agreement, the term "disability" will
mean a total and permanent disability as determined by the Board of Directors in
its sole discretion.

         (b) If the employment of Participant terminates by reason of death,
Participant's Beneficiary (as hereinafter defined) may exercise the Option for a
period of one year after the date of death and not thereafter; provided,
however, that no Option or portion thereof will be exercisable after it has
expired pursuant to Section 1 hereof.

         (c) If the employment of Participant is terminated by the Company
without Cause (as hereinafter defined) or is terminated by Participant for any
reason other than death or disability, Participant (or his or her legal
representative) may exercise any portion of the Option which has vested pursuant
to Section 1 hereof as of the date of such termination of employment for a
period of three months after the date of such termination of employment and not
thereafter.

         (d) If the employment of the Participant terminates for Cause, the
entire Option (whether vested or non-vested) will immediately be forfeited and
become null and void. For purposes hereof, "Cause" will mean material
nonfeasance, material malfeasance or material misfeasance on the part of the
Participant which, if susceptible of cure, will continue after notice of the
default and a reasonable opportunity to cure.

      4.    Withholding. If any part of this Option is not permitted to be an
Incentive Stock Option under the Code, then the Participant agrees to pay to the
Company such amount as is requested by the Company for the purpose of satisfying
the Company's

                                       2
<PAGE>
obligation to withhold federal, state or local taxes in connection with any
exercise of any non-qualified portion of this Option. The Participant may elect
to satisfy such withholding obligation, in whole or in part, (a) by causing the
Company to withhold shares otherwise issuable pursuant to the exercise of the
Option or (b) by delivering to the Company shares already owned by the
Participant. The Shares so delivered or withheld will be a whole number, have a
Fair Market Value equal to such withholding obligation as of the date that the
amount of tax to be withheld is to be determined, will be free of all adverse
claims, and will be duly endorsed in blank by Participant or accompanied by
stock powers duly endorsed in blank.

      5.    Nonalienation. Participant will have no rights to sell, assign,
transfer, pledge, or otherwise alienate the Option under this Agreement, except
by will or by the laws of descent, and any such attempted sale, assignment,
transfer, pledge or other conveyance will be null and void. The Option will be
exercisable during the Participant's lifetime only by the Participant (or his or
her legal representative).

      6.    Beneficiary. The person whose name appears on the signature page
hereof after the caption "Beneficiary" or any successor designated by
Participant in accordance herewith (the person who is Participant's Beneficiary
at the time of his or her death is referred to as the "Beneficiary") will be
entitled to exercise the Option, to the extent it is exercisable, after the
death of Participant. Participant may from time to time revoke or change his or
her Beneficiary designation without the consent of any prior Beneficiary by
filing a new designation with the Board of Directors. The last such designation
received by the Board of Directors will be controlling; provided, however, that
no designation, or change or revocation thereof, will be effective unless
received by the Board of Directors prior to Participant's death, and in no event
will any designation be effective as of a date prior to such receipt. If no
Beneficiary designation is in effect at the time of Participant's death, or if
no designated Beneficiary survives Participant or if such designation conflicts
with law, Participant's estate will be entitled to exercise the Option, to the
extent it is exercisable after the death of Optionee. If the Board of Directors
is in doubt as to the right of any person to exercise the Option, the Company
may refuse to recognize such exercise, without liability for any interest or
dividends on the underlying Shares, until the Board of Directors determines the
person entitled to exercise the Option, or the Company may file an interpleader
action with any court of appropriate jurisdiction and such application will be a
complete discharge of the liability of the Company therefor.

      7.    Securities Law Restrictions. The Participant acknowledges that he is
acquiring the Option and the shares purchasable pursuant to the Option for
investment purposes only and not with a view to resale or other distribution
thereof to the public in violation of the Securities Act of 1933, as amended
(the "Act"). Participant agrees and acknowledges with respect to any shares that
have not been registered under the Act, that (i) Participant will not sell or
otherwise dispose of such shares except pursuant to an effective registration
statement under the Act and any applicable state securities laws, or

                                       3
<PAGE>
in a transaction which in the opinion of counsel for the Company, is exempt from
such registration, and (ii) a legend will be placed on the certificates for the
shares to such effect.

      8.    Limited Interest.

         (a) The grant of the Option will not be construed as giving Participant
any interest other than as provided in this Agreement.

         (b) Participant will have no rights as a shareholder as a result of the
grant of the Option, until the Option is exercised, the exercise price is paid,
and the shares are issued thereunder.

         (c) The grant of the Option will not confer on Participant any right to
continue as an employee, nor interfere in any way with the right of the Company
to terminate the Participant's employment at any time.

         (d) The grant of the Option will not affect in any way the right or
power of the Company to make or authorize any or all adjustments,
recapitalizations, reorganizations, or other changes in the Company's capital
structure or its business, or any merger, consolidation or business combination
of the Company, or any issuance or modification of any term, condition, or
covenant of any bond, debenture, debt, preferred stock or other instrument ahead
of or affecting the shares or the rights of the holders thereof, or the
dissolution or liquidation of the Company, or any sale or transfer of all or any
part of its assets or business or any other Company act or proceeding, whether
of a similar character or otherwise.

      9.    Right of First Refusal. The shares purchasable pursuant to the
Option are subject to a right of first refusal as described in this Section.

            a.    Right of First Refusal Transfer Notice. If at any time the
                  Participant proposes to transfer the shares to one or more
                  third parties under an understanding with a third party (a
                  "Transfer"), then the Participant will give the Company and
                  each other stockholder written notice of Participant's
                  intention to make the Transfer (the "Transfer Notice"), which
                  Transfer Notice must include (i) a description of the shares
                  to be transferred ("Offered Shares"), (ii) the identity of the
                  prospective transferee(s), and (iii) the consideration and the
                  material terms and conditions upon which the proposed Transfer
                  is to be made. The Transfer Notice will certify that
                  Participant has received a firm offer from the prospective
                  transferee(s) and in good faith believes a binding agreement
                  for the Transfer is obtainable on the terms set forth in the
                  Transfer Notice. The Transfer Notice will also include a

                                       4
<PAGE>
                  copy of any written proposal, term sheet or letter of intent
                  or other agreement relating to the proposed Transfer.

            b.    Company's Option. The Company has an option for a period of
                  ten (10) days from receipt of the Transfer Notice to elect to
                  purchase the Offered Shares at the same price and subject to
                  the same material terms and conditions as described in the
                  Transfer Notice. The Company may exercise this purchase option
                  and purchase all (or a portion of) the Offered Shares by
                  notifying Participant in writing before expiration of the ten
                  (10) day period as to the number of shares it wishes to
                  purchase. If the Company gives Participant notice that it
                  desires to purchase the shares, then payment of the Offered
                  Shares will be by check or wire transfer, against delivery of
                  the Offered Shares to be purchased at a place agreed upon
                  between the parties and at the time of the scheduled closing
                  therefor, which will be no later than forty-five (45) days
                  after the Company's receipt of the Transfer Notice, unless the
                  Transfer Notice contemplated a later closing with the
                  prospective third party transferee(s) or unless the value of
                  the purchase price has not yet been established. If the
                  Company fails to purchase all of the Offered Shares by
                  exercising the option granted in this Section within the
                  period provided, the Offered Shares will be subject to the
                  options granted to the other stockholders.

            c.    Additional Transfer Notice. Subject to the Company's right set
                  forth in Section 9(b), if Participant proposes a Transfer,
                  then, after the Company has declined to purchase all, or a
                  portion of, the Offered Shares, the Stockholder will give each
                  other stockholder an "Additional Transfer Notice" that
                  includes all of the information and certifications required in
                  a Transfer Notice and will additionally identify the Offered
                  Shares that the Company has declined to purchase (the
                  "Remaining Shares") and briefly describe the other
                  stockholders' rights of first refusal and co-sale rights with
                  respect to the proposed Transfer.

            d.    Other Stockholders' Option. The other stockholders have an
                  option for a period of twenty (20) days from the receipt of
                  the Additional Transfer Notice from Participant set forth in
                  Section 9(c) to elect to purchase their respective pro rata
                  shares of the Remaining Shares at the same price and subject
                  to the same material terms and conditions as described in the
                  Additional Transfer Notice. Each of the other stockholders may
                  exercise the purchase option and, thereby, purchase all or any
                  portion of his, her or its pro rata share (with any

                                       5
<PAGE>
                  reallotments as provided below) of the Remaining Shares, by
                  notifying Participant and the Company in writing, before
                  expiration of the twenty (20) day period as to the number of
                  such shares that he, she, or it wishes to purchase (including
                  any reallotment). Each of the other stockholders' pro rata
                  share of the Remaining Shares will be a fraction of the
                  Remaining Shares, of which the number of shares of Common
                  stock owned by the other stockholder on the date of the
                  Transfer Notice will be the numerator and the total number of
                  shares of Common Stock held by the other stockholder and all
                  other stockholders on the date of the Transfer Notice will be
                  the denominator. Each of the other stockholders will have a
                  right of reallotment that, if any of the stockholders fails to
                  exercise the right to purchase its full pro rata share of the
                  Remaining Shares, the other participating stockholders may
                  exercise an additional right to purchase, on a pro rata basis,
                  the Remaining Shares not previously purchased. Each
                  stockholder is entitled to apportion Remaining Shares to be
                  purchased among its partners and affiliates, provided that the
                  stockholder notifies Participant of this allocation. If a
                  stockholder gives Participant notice that it desires to
                  purchase its pro rata share of the Remaining Shares and, as
                  the case may be , its reallotment, then payment for the
                  Remaining Shares will be by check or wire transfer, against
                  delivery of the Remaining Shares to be purchased at a place
                  agreed upon between the parties and at the time of the
                  scheduled closing, which will be no later than forty-five (45)
                  days after the Company's receipt of the Transfer Notice,
                  unless the Transfer Notice contemplated a later closing with
                  the prospective third party transferee(s) or unless the value
                  of the purchase price has not yet been established.

            e.    The value of the shares purchasable pursuant to the Option
                  will be established by reference to the bona fide third party
                  offer or if the consideration is other than cash, the
                  Company's Board of Directors will determine the value of the
                  shares.

            f.    Legend. Each existing or replacement certificate for shares
                  now owned or hereafter acquired by the other stockholders will
                  bear the following legend upon its face: The sale, pledge,
                  hypothecation, assignment, or transfer of the securities
                  represented by this certificate is subject to the terms and
                  conditions of a right of first refusal between the stockholder
                  and the corporation described in the Incentive Stock Option
                  Agreement. Copies of this agreement may be obtained upon
                  written request to the secretary of the corporation.

                                       6
<PAGE>
            g.    This right of first refusal terminates on the earlier of (i)
                  the quotation of the Common Stock on the Nasdaq Small Cap or
                  National Market System and (ii) the closing of the Company's
                  sale of all or substantially all of its assets or the
                  acquisition of the Company by another entity by means of
                  merger, consolidation, or other transaction or series of
                  related transactions resulting in the exchange of the
                  outstanding shares of the Company's capital stock such that
                  the stockholders of the Company prior to the transaction own,
                  directly or indirectly, less than 50% of the voting power of
                  the surviving entity.

      10. Lock-up. Participant may not, without the prior written consent of the
Company's Board of Directors, during the period commencing on the date that the
Common Stock begins trading on Nasdaq and ending on the date two years after the
beginning trading date (i) lend, offer, pledge, sell, contract to sell, sell any
option or contract to purchase, purchase any option or contract to sell, grant
any option, right or warrant to purchase, otherwise transfer or dispose of,
directly or indirectly, any shares of the Common Stock or any securities
convertible into or exercisable or exchangeable for Common Stock (whether such
shares or any such securities are then owned by Participant or are thereafter
acquired), or (ii) enter into any swap or other arrangement that transfers to
another, in whole or in part, any of the economic consequences of ownership of
the Common Stock, whether any such transaction described in clause (i) and (ii)
above is to be settled by delivery of Common Stock or such other securities, in
cash or otherwise. In order to enforce the covenant in this Section, the Company
may imposed stop-transfer instructions with respect to the shares of Participant
until the end of the relevant period.

      11. Incorporation by Reference. The terms of the Plan to the extent not
stated herein are expressly incorporated herein by reference and in the event of
any conflict between this Agreement and the Plan, the Plan will govern.

      12. Governing Law. This Agreement will be governed by and construed in
accordance with the laws of the State of California.

      13. Amendment. This Agreement may not be amended, modified, terminated or
otherwise altered except by the written consent of the parties hereto.

      14. Counterparts. This Incentive Stock Option Agreement may be executed in
one or more counterparts, each of which will be deemed to be an original but all
of which together will constitute one and the same instrument.

                                       7
<PAGE>
         IN WITNESS WHEREOF, the Company has caused this instrument to be
executed by its duly authorized officer and its corporate seal hereunto affixed,
and the Optionee has hereunto affixed his or her hand, all on the day and year
set forth below.

                                          LIPID SCIENCES, INC.

                                          By: ______________________________
                                          Its:______________________________

                                                       ("Company")

                                          _________________________________
                                          Name:____________________________

                                                     ("Participant")

No. of Shares:               ______      Grant Date:                ______

Exercise Price Per Share:   $______      Initial Exercise Date:    ________, __

Date of Agreement:           ______      Option Expiration Date:   _________

Beneficiary:_______________________      Address of Beneficiary:

                                         __________________________________

Beneficiary Tax Identification No.:

___________________________________      __________________________________

                                       8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00030-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00030-of-00352.parquet"}]]